Hypothesis

Pathogenic mitochondrial DNA heteroplasmy in hematopoietic stem cells shifts the mitochondrial ROS set‑point, stabilizes HIF‑1α, and drives a niche‑remodeling program that fuels clonal expansion independent of overall mutation load.

Mechanistic Rationale

Clonal hematopoiesis emerges when specific mtDNA mutations reach high heteroplasmy in a subset of stem cells [1]. These mutations do not merely accumulate as passengers; they alter electron‑transport chain flux, increasing superoxide production at Complex I and III [6]. The resulting ROS elevation inhibits prolyl‑hydroxylase domain enzymes, preventing HIF‑1α degradation and allowing its accumulation even under normoxia. Stabilized HIF‑1α transcriptionally upregulates glycolytic enzymes, VEGF, and SDF‑1, reshaping the bone‑marrow niche to favor mutant‑cell retention and proliferation [5]. This creates a feedback loop where niche‑derived cytokines further enhance mitochondrial ROS via NADPH oxidase activation, locking the clone into a self‑reinforcing state. Importantly, biochemical defects in OXPHOS only manifest when heteroplasmy exceeds ~60‑70% [5]; below this threshold, the ROS signal is sufficient for signaling without causing bioenergetic failure, explaining why many aged cells harbor mtDNA mutations yet retain respiration [3].

Testable Predictions

1. In aged mice, hematopoietic stem cells harboring pathogenic mtDNA heteroplasmy will show elevated mitochondrial ROS and nuclear HIF‑1α protein compared with wild‑type counterparts, despite comparable OXPHOS capacity.
2. Pharmacological scavenging of mitochondrial superoxide (e.g., MitoTEMPO) or genetic overexpression of mitochondrially‑targeted catalase will reduce HIF‑1α stabilization and attenuate clonal expansion without lowering overall mtDNA mutation burden.
3. Conversely, forced expression of a ROS‑insensitive, constitutively active HIF‑1α allele will rescue clonal expansion in mice with mitochondrial‑ROS scavenged stem cells, demonstrating epistatic placement of HIF‑1α downstream of mtROS.

Experimental Approach

• Isolate lineage‑negative Sca‑1^+c‑Kit^+ (LSK) cells from young (3 mo) and aged (24 mo) mice. Quantify mtDNA heteroplasmy by duplex sequencing and measure mitochondrial ROS using MitoSOX flow cytometry.
• Assess HIF‑1α protein by intracellular staining and western blot; correlate ROS levels with HIF‑1α signal across heteroplasmy strata.
• Treat aged LSK cultures with MitoTEMPO (500 nM) or transduce with mito‑CAT; evaluate colony‑forming unit‑spleen (CFU‑S) assays and competitive repopulation assays to gauge clonal expansion.
• Generate a knock‑in line expressing a ROS‑resistant HIF‑1α (P402A/P564A) specifically in hematopoietic cells; test whether this construct restores clonal advantage in mito‑CAT‑treated aged mice.
• Single‑cell RNA‑seq of treated versus control LSK populations will identify niche‑remodeling signatures (e.g., upregulated Vegf, Cxcl12) and confirm pathway specificity.

If mitochondrial ROS‑driven HIF‑1α activation is necessary and sufficient for mtDNA‑mediated clonal hematopoiesis, then targeting this signaling axis should decouple mutation load from functional impact, offering a precision strategy to mitigate age‑related clonal expansion without attempting wholesale mtDNA correction.